Debiopharm launches OXTEND-III Phase III trial
Debiopharm has randomised the first patient in the global Phase III clinical trial, OXTEND-III, to assess the safety and efficacy of Debio 4126 in adults with acromegaly.
The study aims to evaluate how Debio 4126 performs in treating acromegaly, focusing on safety and effectiveness in adult participants.
Trial overview
- Global, Phase III trial assessing Debio 4126 for acromegaly.
- Primary objective: safety and efficacy in adults.
- Design and endpoints are oriented toward establishing therapeutic value in comparison to existing standards.
Background
- Debiopharm advances its pipeline with a late-stage study targeting acromegaly, a hormonal disorder caused by excess growth hormone.
- The investigational drug Debio 4126 seeks to address underlying pathophysiology linked to this condition.
What this means
- Moving into Phase III represents a pivotal step to confirm prior Phase II findings and potentially expand treatment options for patients with acromegaly.
- Positive results could lead to, or support, regulatory submissions and eventual market availability.
Author’s summary: Debiopharm advances to Phase III with Debio 4126 for acromegaly, marking a key milestone toward potential new treatment options pending trial outcomes.
More News
- Solidarity on Trial in Greece
- Melissa McCarthy reveals dramatic weight loss in tight gold gown on red carpet
- Melissa McCarthy's Sleek Look After Weight Loss
- Impacts of an industrial deep-sea mining trial on macrofaunal biodiversity
- After Le Scouarnec sexual abuse trial, court faces challenge of compensating victims
- Melissa McCarthy impresses fans with her stunning weight loss while hosting Saturday Night Live
- Collaboration Across Africa Is Key To Increasing Clinical Trials
- Organizer Zippy Monogram Eclipse - For Him de luxe
- Organizer of failed Fyre Festival, Billy McFarland announces new PHNX event
- The Newest V.I.P.s at the U.S. Embassy in South Africa? Afrikaners.